

Mark Sculpher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8974911/publications.pdf>

Version: 2024-02-01

145
papers

10,343
citations

47006

47
h-index

34986

98
g-index

148
all docs

148
docs citations

148
times ranked

12362
citing authors

#	ARTICLE	IF	CITATIONS
1	Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making. <i>Medical Decision Making</i> , 2022, 42, 17-27.	2.4	8
2	Developing the EQ-5D-5L Value Set for Uganda Using the "Lite"™ Protocol. <i>Pharmacoeconomics</i> , 2022, 40, 309-321.	3.3	14
3	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	2.8	9
4	Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research. <i>Substance Use and Misuse</i> , 2022, 57, 815-821.	1.4	5
5	Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010471.	3.0	14
6	Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England. <i>Journal of Evaluation in Clinical Practice</i> , 2021, 27, 119-133.	1.8	8
7	Ideas About Resourcing Health Care in the United States: Can Economic Evaluation Achieve Meaningful Use?. <i>Annals of Internal Medicine</i> , 2021, 174, 80-85.	3.9	9
8	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. <i>Heart</i> , 2021, 107, 381-388.	2.9	12
9	Methodological issues in economic evaluations of emergency transport systems in low-income and middle-income countries. <i>BMJ Global Health</i> , 2021, 6, e004723.	4.7	2
10	Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies. <i>Pharmacoeconomics</i> , 2021, 39, 879-887.	3.3	6
11	Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2649-2666.	1.7	8
12	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. <i>Value in Health</i> , 2021, 24, 1828-1834.	0.3	22
13	Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e418-e442.	1.9	28
14	Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. <i>BMJ Open</i> , 2020, 10, e037075.	1.9	48
15	The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. <i>Trials</i> , 2020, 21, 373.	1.6	3
16	After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?. <i>Pharmacoeconomics</i> , 2020, 38, 247-257.	3.3	13
17	Distributional cost effectiveness analysis of West Yorkshire low emission zone policies. <i>Health Economics (United Kingdom)</i> , 2020, 29, 567-579.	1.7	7
18	The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. <i>Trials</i> , 2019, 20, 483.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of diagnosis as a metric for monitoring effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. <i>Journal of the International AIDS Society</i> , 2019, 22, e25325.	3.0	20
20	Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 577-590.	2.1	73
21	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.	2.5	27
22	ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics. <i>Value in Health</i> , 2018, 21, 171-172.	0.3	6
23	Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema. <i>Current Medical Research and Opinion</i> , 2018, 34, 1927-1932.	1.9	0
24	Supporting the development of a health benefits package in Malawi. <i>BMJ Global Health</i> , 2018, 3, e000607.	4.7	42
25	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. <i>Health Economics (United Kingdom)</i> , 2018, 27, e28-e40.	1.7	2
26	The Use of MCDA in HTA: Great Potential, but More Effort Needed. <i>Value in Health</i> , 2018, 21, 394-397.	0.3	67
27	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial. <i>JACC: Heart Failure</i> , 2018, 6, 517-526.	4.1	59
28	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 15.	1.5	3
29	Economic analysis of service and delivery interventions in health care. <i>Health Services and Delivery Research</i> , 2018, 6, 1-16.	1.4	18
30	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	2.8	70
31	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. <i>Medical Decision Making</i> , 2017, 37, 148-161.	2.4	18
32	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. <i>Health Economics (United Kingdom)</i> , 2017, 26, 109-123.	1.7	52
33	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. <i>Value in Health</i> , 2017, 20, 234-239.	0.3	64
34	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 705-716.	0.7	11
35	Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2017, 390, 1048-1060.	13.7	448
36	Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial. <i>Advances in Therapy</i> , 2017, 34, 753-764.	2.9	26

#	ARTICLE	IF	CITATIONS
37	Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure. <i>Open Heart</i> , 2017, 4, e000726.	2.3	2
38	Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771644.	0.9	8
39	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. <i>PLoS ONE</i> , 2017, 12, e0172749.	2.5	51
40	Acupuncture for chronic pain and depression in primary care: a programme of research. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-316.	1.0	27
41	Cancer Drugs Fund requires further reform. <i>BMJ, The</i> , 2016, 354, i5090.	6.0	26
42	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. <i>Heart</i> , 2016, 102, 1742-1749.	2.9	30
43	Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. <i>Value in Health</i> , 2016, 19, 929-935.	0.3	589
44	Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. <i>Pharmacoeconomics</i> , 2016, 34, 795-804.	3.3	9
45	Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 125-140.	4.0	49
46	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. <i>Value in Health</i> , 2016, 19, 431-439.	0.3	20
47	Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. <i>BMC Medical Research Methodology</i> , 2016, 16, 131.	3.1	11
48	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1051.	7.4	227
49	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	4.0	13
50	Should the Lambda (λ) Remain Silent?. <i>Pharmacoeconomics</i> , 2016, 34, 323-329.	3.3	6
51	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. <i>Value in Health</i> , 2016, 19, 138-144.	0.3	24
52	Using electronic health records to predict costs and outcomes in stable coronary artery disease. <i>Heart</i> , 2016, 102, 755-762.	2.9	26
53	The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. <i>Health Technology Assessment</i> , 2016, 20, 1-158.	2.8	11
54	The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-348.	2.8	71

#	ARTICLE	IF	CITATIONS
55	CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?. Health Economics (United Kingdom), 2015, 24, 1-7.	1.7	88
56	Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. Journal of Psychosomatic Research, 2015, 79, 465-470.	2.6	37
57	Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. American Heart Journal, 2015, 169, 17-24.e1.	2.7	25
58	Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis. Value in Health, 2015, 18, 141-142.	0.3	13
59	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
60	Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients. Journal of the International AIDS Society, 2014, 17, 19498.	3.0	6
61	Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart, 2014, 1, e000155.	2.3	33
62	Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. European Journal of Haematology, 2014, 92, 249-255.	2.2	10
63	The economics of medicines optimization: policy developments, remaining challenges and research priorities. British Medical Bulletin, 2014, 111, 45-61.	6.9	10
64	Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?. Lancet Infectious Diseases, The, 2014, 14, 650-655.	9.1	38
65	Reforming the Cancer Drug Fund. BMJ, The, 2014, 349, g7276-g7276.	6.0	7
66	Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial. PLoS ONE, 2014, 9, e113726.	2.5	13
67	Effect of management strategies and clinical status on costs of care for advanced HIV. American Journal of Managed Care, 2014, 20, e129-37.	1.1	5
68	The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology, 2013, 82, e342-e349.	2.6	49
69	Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of Medical Economics, 2013, 16, 510-521.	2.1	15
70	Acupuncture and Counselling for Depression in Primary Care: A Randomised Controlled Trial. PLoS Medicine, 2013, 10, e1001518.	8.4	106
71	Understanding Harris's understanding of CEA: Is cost effective resource allocation undone?. Journal of Health Services Research and Policy, 2013, 18, 34-39.	1.7	4
72	Methods Development for Health Technology Assessment. Medical Decision Making, 2013, 33, 313-315.	2.4	0

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. <i>Heart</i> , 2013, 99, 873-881.	2.9	90
74	NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. <i>BMJ Open</i> , 2012, 2, e000671.	1.9	17
75	Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. <i>Medical Decision Making</i> , 2012, 32, 70-82.	2.4	12
76	Real Economics Needs to Reflect Real Decisions. <i>Pharmacoeconomics</i> , 2012, 30, 133-136.	3.3	13
77	Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions. <i>Value in Health</i> , 2012, 15, 570-579.	0.3	101
78	Valutazione di tecnologia singola presso l'Istituto Nazionale per l'Eccellenza Sanitaria e Clinica del Regno Unito. <i>Pharmacoeconomics Italian Research Articles</i> , 2011, 13, 5-8.	0.2	0
79	Alitretinoina nell'eczema cronico grave alle mani. Valutazione di tecnologia singola presso il NICE. <i>Pharmacoeconomics Italian Research Articles</i> , 2011, 13, 9-20.	0.2	0
80	Sins of omission and obfuscation: IQWiG's guidelines on economic evaluation methods. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1132-1136.	1.7	28
81	Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms. <i>Value in Health</i> , 2010, 13, 112-118.	0.3	22
82	Eliciting Distributions to Populate Decision Analytic Models. <i>Value in Health</i> , 2010, 13, 557-564.	0.3	47
83	Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study. <i>Value in Health</i> , 2010, 13, 565-572.	0.3	14
84	Reflecting Heterogeneity in Patient Benefits: The Role of Subgroup Analysis with Comparative Effectiveness. <i>Value in Health</i> , 2010, 13, S18-S21.	0.3	11
85	What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?. <i>Value in Health</i> , 2010, 13, 1028-1037.	0.3	77
86	Value for money and the Quality and Outcomes Framework in primary care in the UK NHS. <i>British Journal of General Practice</i> , 2010, 60, e213-e220.	1.4	61
87	Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 175-182.	0.5	8
88	Glycopeptide vs. Non-Glycopeptide Antibiotics for Prophylaxis of Surgical Site Infections: A Systematic Review. <i>Surgical Infections</i> , 2010, 11, 455-462.	1.4	25
89	Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies. <i>Value in Health</i> , 2009, 12, 193-201.	0.3	29
90	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2009, 12, 409-418.	0.3	395

#	ARTICLE	IF	CITATIONS
91	Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods. <i>Value in Health</i> , 2009, 12, 739-749.	0.3	123
92	Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations. <i>Health Policy</i> , 2009, 93, 85-92.	3.0	227
93	Economic Evaluation of Coronary Artery Bypass Grafting Surgery With and Without Cardiopulmonary Bypass: Cost-Effectiveness and Quality-Adjusted Life Years in a Randomized Controlled Trial. <i>Artificial Organs</i> , 2008, 32, 891-897.	1.9	25
94	Subgroups and Heterogeneity in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2008, 26, 799-806.	3.3	129
95	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. <i>Giornale Italiano Di Health Technology Assessment</i> , 2008, 1, 1-14.	0.1	0
96	Quality-adjusted life years. <i>Practical Neurology</i> , 2008, 8, 175-182.	1.1	98
97	The Value of Implementation and the Value of Information: Combined and Uneven Development. <i>Medical Decision Making</i> , 2008, 28, 21-32.	2.4	127
98	Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling. <i>Medical Decision Making</i> , 2007, 27, 471-490.	2.4	33
99	Searching for a threshold "Not so". <i>Journal of Health Services Research and Policy</i> , 2007, 12, 190-191.	1.7	2
100	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 56-58.	1.7	155
101	Efficiency, Equity, and Budgetary Policies. <i>Medical Decision Making</i> , 2007, 27, 128-137.	2.4	56
102	Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?. <i>Value in Health</i> , 2006, 9, 244-252.	0.3	49
103	Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. <i>Health Economics (United Kingdom)</i> , 2006, 15, 373-381.	1.7	71
104	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics (United Kingdom)</i> , 2006, 15, 1-4.	1.7	79
105	Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease. <i>Journal of Health Services Research and Policy</i> , 2006, 11, 225-230.	1.7	24
106	Making decisions under uncertainty-the role of probabilistic decision modelling. <i>Family Practice</i> , 2006, 23, 391-392.	1.9	5
107	An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery. <i>Medical Decision Making</i> , 2006, 26, 480-496.	2.4	47
108	Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 165-171.	0.5	202

#	ARTICLE	IF	CITATIONS
109	Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?. <i>Value in Health</i> , 2005, 8, 433-446.	0.3	93
110	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , 2005, 14, 339-347.	1.7	368
111	Estimating utility data from clinical indicators for patients with stable angina. <i>European Journal of Health Economics</i> , 2005, 6, 347-353.	2.8	51
112	Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. <i>Medical Decision Making</i> , 2005, 25, 511-519.	2.4	32
113	Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. <i>Medical Decision Making</i> , 2005, 25, 493-510.	2.4	25
114	Should Patients Have a Greater Role in Valuing Health States?. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 201-208.	2.1	139
115	Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service?. <i>International Journal of Cardiology</i> , 2005, 100, 229-240.	1.7	39
116	Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 165-71.	0.5	96
117	Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial. <i>BMJ: British Medical Journal</i> , 2004, 328, 134-0.	2.3	138
118	The Use of Probabilistic Decision Models in Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2004, 3, 79-89.	2.1	45
119	Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. <i>BMJ: British Medical Journal</i> , 2004, 328, 382.	2.3	120
120	Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine. <i>Pharmacoeconomics</i> , 2002, 20, 91-100.	3.3	52
121	A rational framework for decision making by the National Institute For Clinical Excellence (NICE). <i>Lancet, The</i> , 2002, 360, 711-715.	13.7	378
122	Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. <i>Social Science and Medicine</i> , 2002, 54, 1369-1377.	3.8	34
123	Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Authors' reply. <i>Health Economics (United Kingdom)</i> , 2002, 11, 653-654.	1.7	8
124	Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. <i>Intensive Care Medicine</i> , 2002, 28, 599-608.	8.2	64
125	Using Economic Evaluations to Reduce the Burden of Asthma and Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2001, 19, 21-25.	3.3	8
126	Recognizing diversity in public preferences: The use of preference sub-groups in cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 2001, 10, 317-324.	1.7	56

#	ARTICLE	IF	CITATIONS
127	Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics (United Kingdom), 2001, 10, 779-787.	1.7	885
128	A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 340-346.	2.3	17
129	Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics, 2000, 17, 461-477.	3.3	172
130	Benefit Valuation in Economic Evaluation of Cancer Therapies. Pharmacoeconomics, 1999, 16, 17-31.	3.3	4
131	The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. , 1998, 7, 129-142.		26
132	An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998, 13, 397-409.	3.3	713
133	A Cost-Utility Analysis of Abdominal Hysterectomy Versus Transcervical Endometrial Resection for the Surgical Treatment of Menorrhagia. International Journal of Technology Assessment in Health Care, 1998, 14, 302-319.	0.5	42
134	The Cost Implications of an Asthma Attack. Pediatric Asthma, Allergy and Immunology, 1998, 12, 193-198.	0.2	7
135	The Costs and Benefits of Primary Total Hip Replacement:How Likely Are New Prostheses To Be Cost-effective?. International Journal of Technology Assessment in Health Care, 1998, 14, 743-761.	0.5	20
136	The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment. Journal of Health Services Research and Policy, 1997, 2, 26-30.	1.7	161
137	9 Economic evaluation in obstetrics and gynaecology. Bailliere's Clinical Obstetrics and Gynaecology, 1996, 10, 661-675.	0.6	0
138	A Cost-Utility Analysis of Laser-Assisted Angioplasty for Peripheral Arterial Occlusions. International Journal of Technology Assessment in Health Care, 1996, 12, 104-125.	0.5	34
139	Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation. International Journal of Technology Assessment in Health Care, 1996, 12, 698-713.	0.5	47
140	The Economic Evaluation of the FIRST Study: Design of a prospective analysis alongside a multinational phase III clinical trial. Contemporary Clinical Trials, 1996, 17, 304-315.	1.9	29
141	Sensitivity analysis in economic evaluation: A review of published studies. Health Economics (United Kingdom), 1994, 3, 95-104.	1.7	399
142	Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics (United Kingdom), 1994, 3, 95-104.	1.7	487
143	Cost of coronary angioplasty versus coronary artery bypass surgery. Lancet, The, 1994, 344, 1574-1575.	13.7	3
144	From impact evaluation to decision-analysis: assessing the extent and quality of evidence on the value for money in health impact evaluations in low- and middle-income countries. Gates Open Research, 0, 5, 1.	1.1	3

#	ARTICLE	IF	CITATIONS
145	Modelling the Health and Economic Impacts of Population-Wide Testing, Contact Tracing and Isolation (PTTI) Strategies for COVID-19 in the UK. SSRN Electronic Journal, 0, , .	0.4	15